ELECSYS ANTI-HBC IGM IMMUNOASSAY AND ELECSYS PRECICONTROL ANTI-HBC IGM

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P110022

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the elecsys anti-hbc igm immunoassay and elecsys precicontrol anti-hbc igm for use on the cobas e 601 immunoassay analyzer. This device is indicated for: the elecsys anti-hbc igm immunoassay is intended for the in vitro qualitative determination of igm antibodies to hepatitis b core antigen (anti-hbc igm) in human serum or plasma (potassium edta, lithium heparin. Sodium heparin, sodium citrate) in adult patients with symptoms of hepatitis or who may be at risk for hepatitis b (1ibv) injection. The presence of anti-hbc igm. In conjunction with other laboratory results and clinical information, is indicative of acute or recent hepatitis b virus (hbv) infection. The elecsys anti-hbc igm immunoassay's performance has not been established for the monitoring of hbv disease or therapy. The electrochemilu-minescence immunoassay "eclia" is intended for use on the cobas e 601 immunoassay analyzer. Precicontroi anti-hbc igm elecsys precicontrol anti-hbc igm is used for quality control of the elecsys anti-hbc igm immunoassay on the cobas e 601 immunoassay analyzer.

DeviceELECSYS ANTI-HBC IGM IMMUNOASSAY AND ELECSYS PRECICONTROL ANTI-HBC IGM
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantROCHE DIAGNOSTICS CORP.
Date Received2011-05-09
Decision Date2011-10-26
Notice Date2011-11-04
PMAP110022
SupplementS
Product CodeLOM
Docket Number11M-0786
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS CORP. 9115 Hague Road p.o. Box 50416 indianapolis, IN 46250-0457
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P110022Original Filing
S028 2021-12-02 30-day Notice
S027 2018-10-26 Normal 180 Day Track No User Fee
S026 2018-10-09 30-day Notice
S025 2018-04-17 Real-time Process
S024 2017-10-11 Real-time Process
S023 2017-08-03 30-day Notice
S022 2017-07-06 Normal 180 Day Track
S021 2017-05-24 30-day Notice
S020 2016-12-07 Real-time Process
S019 2016-09-07 Normal 180 Day Track No User Fee
S018 2016-07-11 135 Review Track For 30-day Notice
S017 2016-02-16 30-day Notice
S016 2016-01-27 30-day Notice
S015 2016-01-27 135 Review Track For 30-day Notice
S014 2015-10-07 30-day Notice
S013 2014-10-16 Real-time Process
S012 2014-04-04 Real-time Process
S011 2013-07-19 Special (immediate Track)
S010
S009 2012-11-30 30-day Notice
S008 2012-08-31 Normal 180 Day Track
S007
S006 2012-02-29 30-day Notice
S005 2012-02-02 30-day Notice
S004 2012-02-02 30-day Notice
S003 2012-02-02 30-day Notice
S002 2012-01-31 135 Review Track For 30-day Notice
S001 2012-01-31 Normal 180 Day Track No User Fee

NIH GUDID Devices

Device IDPMASupp
07613336153932 P110022 022

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.